AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32990629 — intervention group
Group type: COMPARATOR
Intervention: Usual-care DOT
Number of subjects: 144
Study 32990836 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCO
Number of subjects: 12
Study 32990938 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release dinalbuphine sebacate (ERDS)
Number of subjects: 110
Study 32990938 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (PCA) with fentanyl
Number of subjects: 110
Study 32990945 — intervention group
Group type: COMPARATOR
Intervention: Pine bark extract supplements
Number of subjects: 1641
Study 32991114 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly group (≥ 65 years)
Number of subjects: 446
Study 32991114 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recurrence of VTE
Number of subjects: 446
Study 32991114 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding events
Number of subjects: 446
Study 32991114 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and recurrence association
Number of subjects: 446
Study 32991242 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Breast Tomosynthesis (DBT)
Number of subjects: 0
Study 32991242 — intervention group
Group type: COMPARATOR
Intervention: Traditional breast cancer screening methods
Number of subjects: 0
Study 32991329 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG against SARS-CoV-2 spike RBD
Number of subjects: 509
Study 32991329 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies to multiple SARS-CoV-2 antigens
Number of subjects: 509
Study 32991329 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG to the RBD
Number of subjects: 509
Study 32991329 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies to HCoV-OC43 and HCoV-HKU1 spike S2
Number of subjects: 509
Study 32991329 — intervention group
Group type: COMPARATOR
Intervention: Coinfection with influenza
Number of subjects: 509
Study 32991411 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus-based immunosuppression
Number of subjects: 100
Study 32992048 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting-enzyme inhibitors (ACEI)
Number of subjects: 4069
Study 32992048 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-receptor blockers (ARB)
Number of subjects: 4069
Study 32992048 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI or ARB combined
Number of subjects: 4069
Study 32992048 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of 19 studies
Number of subjects: 4069
Study 32992341 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy (3 cycles) followed by AVD chemotherapy (4 to 6 cycles)
Number of subjects: 30
Study 32992341 — intervention group
Group type: EXPERIMENTAL
Intervention: AVD chemotherapy (after pembrolizumab)
Number of subjects: 30
Study 32992341 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy followed by AVD
Number of subjects: 30
Study 32993275 — intervention group
Group type: EXPERIMENTAL
Intervention: BPH screening tool (score ≥3) and serum PSA ≥2 ng/mL
Number of subjects: 561
Study 32993275 — intervention group
Group type: COMPARATOR
Intervention: IPSS ≥8 and serum PSA ≥2 ng/mL
Number of subjects: 561
Study 32993521 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels measured prior to catheter ablation
Number of subjects: 711
Study 32993521 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels analyzed as continuous variable
Number of subjects: 711
Study 32993521 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP cut-off of 3 mg/l
Number of subjects: 711
Study 32993559 — intervention group
Group type: EXPERIMENTAL
Intervention: UCP-LF CAA urine test
Number of subjects: 0
Study 32993559 — intervention group
Group type: EXPERIMENTAL
Intervention: PZQ treatment immediately after diagnosis
Number of subjects: 0
Study 32993559 — intervention group
Group type: COMPARATOR
Intervention: PZQ treatment after delivery
Number of subjects: 0
Study 32993559 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal study
Number of subjects: 0
Study 32993716 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine preoperative carotid and lower limb ultrasound screening
Number of subjects: 360
Study 32993772 — intervention group
Group type: EXPERIMENTAL
Intervention: Total alpha-synuclein levels in CSF in AD patients
Number of subjects: 166
Study 32993772 — intervention group
Group type: COMPARATOR
Intervention: Total alpha-synuclein levels in CSF in DLB patients
Number of subjects: 166
Study 32993772 — intervention group
Group type: COMPARATOR
Intervention: Combination of Alzheimer's biomarkers (t-Tau, P-Tau, Aβ42, Aβ40)
Number of subjects: 166
Study 32993772 — intervention group
Group type: EXPERIMENTAL
Intervention: Total alpha-synuclein levels in CSF
Number of subjects: 166
Study 32993772 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding alpha-synuclein total to Alzheimer's biomarkers
Number of subjects: 166
Study 32993784 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab treatment
Number of subjects: 107
Study 32993794 — intervention group
Group type: EXPERIMENTAL
Intervention: BEZ235 (300-400 mg BID)
Number of subjects: 24
Study 32993794 — intervention group
Group type: EXPERIMENTAL
Intervention: BEZ235 (300 mg BID)
Number of subjects: 24
Study 32993794 — intervention group
Group type: EXPERIMENTAL
Intervention: BEZ235
Number of subjects: 24
Study 32993811 — intervention group
Group type: EXPERIMENTAL
Intervention: High positive end-expiratory pressure (PEEP) (12-15 cmH2O)
Number of subjects: 30
Study 32993811 — intervention group
Group type: EXPERIMENTAL
Intervention: High positive end-expiratory pressure (PEEP)
Number of subjects: 30
Study 32994225 — intervention group
Group type: EXPERIMENTAL
Intervention: FBG variability (measured using SD, CV, VIM, and average real variability)
Number of subjects: 7699
Study 32994243 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive use of liquefied petroleum gas (LPG)
Number of subjects: 0
Study 32994273 — intervention group
Group type: EXPERIMENTAL
Intervention: STAT1 deletion in adipocytes
Number of subjects: 0
Study 32994273 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32994296 — intervention group
Group type: EXPERIMENTAL
Intervention: Marlboro Gold (n=49)
Number of subjects: 240
Study 32994296 — intervention group
Group type: COMPARATOR
Intervention: Marlboro Red (n=191)
Number of subjects: 240
Study 32994312 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion (BPD) or Roux-en-Y gastric bypass (RYGB)
Number of subjects: 24
Study 32994312 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypassing the jejunum
Number of subjects: 24
Study 32994362 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-mediated inflammatory diseases (IMID)
Number of subjects: 53378
Study 32994362 — intervention group
Group type: EXPERIMENTAL
Intervention: Crohn's disease (CD)
Number of subjects: 53378
Study 32994362 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulcerative colitis
Number of subjects: 53378
Study 32994362 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis (RA)
Number of subjects: 53378
Study 32994362 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriatic arthritis (PsA)
Number of subjects: 53378
Study 32994371 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuxuetong injection
Number of subjects: 2416
Study 32994371 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 2416
Study 32994442 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy use in non-genetic testing (NGT) individuals
Number of subjects: 176
Study 32994442 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy use in carriers of Lynch syndrome
Number of subjects: 176
Study 32994442 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived risk to develop colon cancer
Number of subjects: 176
Study 32994442 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician recommendations for colonoscopy
Number of subjects: 176
Study 32995696 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfotase alfa for 12 months
Number of subjects: 14
Study 32995919 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard IV intermittent bolus paracetamol therapy (15-mg/kg doses as 1-h infusions every 6 h for 5 days)
Number of subjects: 137
Study 32995919 — intervention group
Group type: COMPARATOR
Intervention: Continuous IV paracetamol infusion therapy (60-mg/kg/day continuously for 5 days)
Number of subjects: 137
Study 32995944 — intervention group
Group type: EXPERIMENTAL
Intervention: Pridopidine 90 mg
Number of subjects: 0
Study 32995944 — intervention group
Group type: EXPERIMENTAL
Intervention: Pridopidine 1 mg
Number of subjects: 0
Study 32995944 — intervention group
Group type: EXPERIMENTAL
Intervention: Pridopidine doses ranging from 22.5 to 90 mg
Number of subjects: 0
Study 32996064 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam 3 g (ceftolozane 2 g/tazobactam 1 g)
Number of subjects: 100
Study 32996064 — intervention group
Group type: COMPARATOR
Intervention: Meropenem 1 g
Number of subjects: 100
Study 32996096 — intervention group
Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection (RCI) 80 U subcutaneously every other day to week 4, then twice weekly to week 24
Number of subjects: 169
Study 32996096 — intervention group
Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection (RCI)
Number of subjects: 169
Study 32996096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 32996164 — intervention group
Group type: EXPERIMENTAL
Intervention: CAC (+) group (34 patients diagnosed with CAC)
Number of subjects: 1101
Study 32996164 — intervention group
Group type: COMPARATOR
Intervention: CAC (-) group (1,067 patients without CAC)
Number of subjects: 1101
Study 32996891 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone calls (maximum of 3 calls on different days and times)
Number of subjects: 200
Study 32997124 — intervention group
Group type: EXPERIMENTAL
Intervention: NCCN guidelines-based decision support tool
Number of subjects: 76
Study 32997260 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mechanical ventilation (EMV) via face-mask or endotracheal intubation
Number of subjects: 50
Study 32997260 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (control)
Number of subjects: 50
Study 32997260 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mechanical ventilation (EMV)
Number of subjects: 50
Study 32997632 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI-guided robot-assisted upper-limb training
Number of subjects: 14
Study 32997657 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients
Number of subjects: 26703
Study 32997657 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients aged ≥85 years
Number of subjects: 26703
Study 32997657 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 negative patients
Number of subjects: 26703
Study 32997689 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 200
Study 32997689 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 200
Study 32997689 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum amyloid A (SAA)
Number of subjects: 200
Study 32997689 — intervention group
Group type: EXPERIMENTAL
Intervention: Neopterin (NP)
Number of subjects: 200
Study 32997689 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP/NP ratio
Number of subjects: 200
Study 32997689 — intervention group
Group type: EXPERIMENTAL
Intervention: SAA/NP ratio
Number of subjects: 200
Study 32998542 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 165
Study 32998542 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD-related complications
Number of subjects: 165
Study 32998542 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart transplantation
Number of subjects: 165
Study 32998542 — intervention group
Group type: EXPERIMENTAL
Intervention: Death
Number of subjects: 165
Study 32998750 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies with clinician champions and organizational support
Number of subjects: 12
Study 32998750 — intervention group
Group type: COMPARATOR
Intervention: No champion with necessary characteristics and/or organizational support
Number of subjects: 12
Study 32998751 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF-23 above the median
Number of subjects: 246
Study 32998751 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of GLP-1 analogues
Number of subjects: 246
Study 32998925 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of sleep apnoea syndrome (SAS)
Number of subjects: 60
Study 32998925 — intervention group
Group type: EXPERIMENTAL
Intervention: SAS management parameters and questionnaires
Number of subjects: 60
Study 32998963 — intervention group
Group type: EXPERIMENTAL
Intervention: Itacitinib (INCB039110), a JAK1 inhibitor
Number of subjects: 0
Study 32998963 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32998965 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvocidib (30 mg/m²) followed by 7+3 (Cytarabine 100 mg/m² + Daunorubicin)
Number of subjects: 0
Study 32998965 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvocidib (30 mg/m²)
Number of subjects: 0
Study 32998965 — intervention group
Group type: COMPARATOR
Intervention: 7+3 (Cytarabine + Daunorubicin)
Number of subjects: 0
Study 32999432 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 0
Study 32999466 — intervention group
Group type: EXPERIMENTAL
Intervention: F-18-PSMA-1007-PET
Number of subjects: 53
Study 32999466 — intervention group
Group type: COMPARATOR
Intervention: mpMRI
Number of subjects: 53
Study 32999466 — intervention group
Group type: COMPARATOR
Intervention: Histopathology
Number of subjects: 53
Study 33000389 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTEM testing in Child-Pugh-C patients
Number of subjects: 159
Study 33000389 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTEM testing in compensated Child-Pugh-A patients
Number of subjects: 159
Study 33000389 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTEM parameters in patients with short CFT and high MCF in EXTEM
Number of subjects: 159
Study 33000470 — intervention group
Group type: COMPARATOR
Intervention: Dihydropyridine calcium channel blockers (CCBs)
Number of subjects: 1459
Study 33000661 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation with identified risk factors
Number of subjects: 1033
Study 33000661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac related reason for endotracheal intubation
Number of subjects: 1033
Study 33000661 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-intubation noninvasive ventilation
Number of subjects: 1033
Study 33000661 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency intubation
Number of subjects: 1033
Study 33000661 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-severe difficult bag-mask ventilation
Number of subjects: 1033
Study 33000661 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid administration within the preceding 24 hours
Number of subjects: 1033
Study 33000661 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline oxygenation
Number of subjects: 1033
Study 33000661 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-intubation hypoxemia
Number of subjects: 1033
Study 33000670 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit sources
Number of subjects: 0
Study 33000670 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable sources
Number of subjects: 0
Study 33000670 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 33001035 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable sleep EEG device (Zmachine Insight+, General Sleep Corporation)
Number of subjects: 104
Study 33001035 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable sleep EEG device
Number of subjects: 104
Study 33001035 — intervention group
Group type: EXPERIMENTAL
Intervention: Wristworn actigraph
Number of subjects: 104
Study 33001241 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy with simultaneous integrated boost (SIB)
Number of subjects: 143
Study 33001310 — intervention group
Group type: EXPERIMENTAL
Intervention: MGMT methylation in patients with moderately vascularized tumors (rCBV < 10.73)
Number of subjects: 96
Study 33001310 — intervention group
Group type: EXPERIMENTAL
Intervention: MGMT methylation in patients with highly vascularized tumors (rCBV > 10.73)
Number of subjects: 96
Study 33001310 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI perfusion markers
Number of subjects: 96
Study 33001538 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 62
Study 33001549 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral dorsolateral prefrontal cortex (DLPFC) theta burst stimulation (TBS) treatment for 2 weeks
Number of subjects: 16
Study 33001549 — intervention group
Group type: COMPARATOR
Intervention: Control group of age-matched healthy youths, N=16
Number of subjects: 16
Study 33001967 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 antibodies (detected via lateral flow immunoassay test)
Number of subjects: 590
Study 33002543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (3 mg/kg) and Nivolumab (1 mg/kg) every 3 weeks for 4 doses followed by Nivolumab monotherapy (480 mg) every 4 weeks until progression or up to 1 year after consolidative thoracic radiation therapy (30 Gy in 10 fractions).
Number of subjects: 21
Study 33002543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (3 mg/kg) and Nivolumab (1 mg/kg) with thoracic radiation therapy after platinum chemotherapy.
Number of subjects: 21
Study 33002543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab and Nivolumab treatment.
Number of subjects: 21
Study 33002543 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased cytotoxic T cell (CD3+CD8+) tumor infiltration.
Number of subjects: 21
Study 33002543 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in peripheral blood CD3+CD8+ from baseline to after first dose of IPI/NIVO.
Number of subjects: 21
Study 33002925 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative cognitive performance assessed by Mini-Cog; OR = 1.57; 95% CI, 0.70-3.53; corrected P value >.999
Number of subjects: 238
Study 33002925 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative cognitive performance assessed by Mini-Mental State Examination; OR = 2.75; 95% CI, 1.23-6.13; corrected P value = .052
Number of subjects: 238
Study 33002925 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative cognitive performance assessed by animal verbal fluency test; OR = 1.24; 95% CI, 0.49-3.16; corrected P value >.999
Number of subjects: 238
Study 33002925 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower preoperative Scto2; OR = 1.08; 95% CI, 1.02-1.14; corrected P value = .024 for each point decrease in Scto2
Number of subjects: 238
Study 33003016 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of MAP values ≥85 mm Hg (average 75%)
Number of subjects: 136
Study 33003016 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressor use to elevate MAP
Number of subjects: 136
Study 33003016 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurologic improvement measured by ASIA impairment scale
Number of subjects: 136
Study 33003016 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of elevated MAP values
Number of subjects: 136
Study 33003016 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressor dose
Number of subjects: 136
Study 33003107 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-5 intervention in an animal model of widespread muscle pain
Number of subjects: 0
Study 33003107 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of IL-5 secretion
Number of subjects: 0
Study 33003107 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower percentage of intermediate monocytes (CD14++/CD16+)
Number of subjects: 0
Study 33003107 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater percentage of nonclassical monocytes (CD14+/CD16++)
Number of subjects: 0
Study 33003873 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough sound model
Number of subjects: 2362
Study 33003873 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocalised /ɑ:/ model
Number of subjects: 2362
Study 33004046 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon ion radiotherapy (CIRT) with a total irradiation dose of 48 Gy (RBE) delivered in twelve fractions; concurrent chemotherapy accepted if indicated.
Number of subjects: 25
Study 33004078 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher land use mix-access
Number of subjects: 8185
Study 33004078 — intervention group
Group type: EXPERIMENTAL
Intervention: Existence of many alternative routes in the neighborhood
Number of subjects: 8185
Study 33004078 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow speed of traffic
Number of subjects: 8185
Study 33004078 — intervention group
Group type: EXPERIMENTAL
Intervention: Few drivers exceeding the speed limits
Number of subjects: 8185
Study 33004078 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of land use mix-diversity, better aesthetics, greater safety from crime, presence of crosswalks and pedestrian signals, greater proximity of shopping centers
Number of subjects: 8185
Study 33004078 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher land use mix-diversity
Number of subjects: 8185
Study 33004078 — intervention group
Group type: EXPERIMENTAL
Intervention: More walking/cycling facilities
Number of subjects: 8185
Study 33004078 — intervention group
Group type: EXPERIMENTAL
Intervention: Better aesthetics
Number of subjects: 8185
Study 33004133 — intervention group
Group type: EXPERIMENTAL
Intervention: EN-PESA model (Elastic Net model)
Number of subjects: 1411
Study 33004133 — intervention group
Group type: EXPERIMENTAL
Intervention: EN-PESA model
Number of subjects: 1411
Study 33004133 — intervention group
Group type: COMPARATOR
Intervention: Traditional risk scores (CVD and SCORE)
Number of subjects: 1411
Study 33004387 — intervention group
Group type: EXPERIMENTAL
Intervention: Women exposed to IPV (n=82)
Number of subjects: 123
Study 33004387 — intervention group
Group type: COMPARATOR
Intervention: Women not exposed to IPV (n=41)
Number of subjects: 123
Study 33004395 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Planning Elevated (FPE) initiative
Number of subjects: 0